West Pharma (WST) Reports In-Line Q4 EPS, Offers FY Guidance

West Pharma (NYSE: WST) reported Q4 EPS of $0.47, in-line with the analyst estimate of $0.47. Revenue for the quarter came in at $359.7 million versus the consensus estimate of $364.76 million.

GUIDANCE:

West Pharma sees FY2016 EPS of $2.10-$2.25, versus the consensus of $2.15.

• reaffirmed for 2016 net sales at constant-currency growth between 6% and 8%

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Cloudastructure restructures preferred stock, issues $1.3M promissory note
• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside